I'm LongbridgeAI, I can summarize articles.HeartBeam is shifting its strategy to license its 3D ambulatory ECG platform to partners instead of selling medical devices directly. This reorganization aims for broader global reach, higher capital efficiency, and lower costs. The company plans to expand into heart attack detection, prioritizing clinical evidence, and will tailor the platform for various distribution channels including health systems and OEMs. Further details are expected on the Q2 2026 conference call.
- HeartBeam shifted strategy to license its 3D ambulatory ECG signal platform to established partners, moving away from direct medical device sales. * Reorganization targets broader global reach, higher capital efficiency, streamlined execution, lower costs. * Plans to expand beyond arrhythmia assessment into heart attack detection, prioritizing clinical evidence to support the indication. * Commercial approach centers on tailoring the platform to multiple channels with existing distribution, including health systems, OEMs, national health systems. * More strategy detail slated for the second-quarter 2026 conference call in August. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartbeam Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606241605BIZWIRE_USPR_____20260624_BW011757) on June 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)